1 / 17

Disclosures

Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study. SJ Nicholls, CM Ballantyne , PJ Barter, HB Brewer, JJP Kastelein , A Gordon, J Johansson, N Wong, R Puri , M Borgman , K Wolski and SE Nissen. Disclosures.

august-curry
Download Presentation

Disclosures

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ Barter, HB Brewer, JJP Kastelein, A Gordon, J Johansson, N Wong, R Puri, M Borgman, K Wolski and SE Nissen

  2. Disclosures • Research support: AstraZeneca, Amgen, Anthera, Eli Lilly, Novartis, Resverlogix, InfraReDx, Roche and LipoScience • Consulting and honoraria: AstraZeneca, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Aventis, CSL Behring, Esperion, Boehringer Ingelheim • ASSURE was sponsored by Resverlogix

  3. Steering Committee • Steven Nissen (Chair) • Stephen Nicholls (Principal Investigator) • Christie Ballantyne • Philip Barter • Bryan Brewer • John Kastelein • Jan Johansson (non-voting)

  4. Background • There remains considerable interest in the development of novel agents that promote the biological activity of HDL. • Induction of synthesis of apoA-I is a novel therapeutic approach to the generation of functional HDL particles • The bromodomain and extra-terminal (BET) protein inhibitor, RVX-208, induces apoA-I synthesis, with favorable effects on HDL related measures and cholesterol efflux. • The impact of RVX-208 on atherosclerotic plaque in humans has not been investigated.

  5. Objective To evaluate the early effects of RVX-208 100 mg bid on progression of coronary atherosclerosis compared to baseline assessed by intravascular ultrasound when administered for 26 weeks to patients with coronary disease and low HDL-C levels.

  6. ASSURE Study Design 323 patients with symptomatic CAD (angiographic stenosis >20%) and low HDL-C levels Placebo (n=80) RVX-208 100 mg bid (n=243) Visit: Week: 1 –4 2 0 3 2 4 4 5 6 6 8 7 11 8 14 9 17 10 20 11 26 11 23 IVUS IVUS Randomization Period Screening Period

  7. ASSURE Trial: Flow of Patients 676 patients screened and 323 patients treated at centers in Europe and South America 3:1 Randomization 26 weekstreatment Placebo (n=80) RVX-208 100 mg bid (n=243) 42 (13%) patients withdrew or did not have an evaluable final IVUS Follow-up IVUS of originally imaged “target” vessel (n=281)

  8. Clinical Characteristics

  9. Baseline Laboratory and Plaque Measures

  10. Change in Biochemical Parameters

  11. Primary IVUS Efficacy Parameter Median Change Percent Atheroma Volume P=0.81† Change Percent Atheroma Volume -0.30 P=0.23* -0.40 P=0.08* * Primary endpoint: comparison from baseline † comparison between groups.

  12. Secondary IVUS Efficacy Parameters -1.3 P=0.01* P=0.86† Change Atheroma Volume (mm3) -2.2 P<0.001* P=0.79† -3.8 -4.2 P=0.01* P<0.001* Whole Segment Most Diseased 10-mm Placebo RVX-208 † comparison between groups. * comparison from baseline

  13. Fraction of Patients Exhibiting Regression 56.2% 56.3% 55.3% 54.8% Percent of Patients P=0.99 P=0.94 Percent Atheroma Volume Total AtheromaVolume Placebo RVX-208

  14. Exploratory Analysis: Plaque Composition P=0.04 P=0.007 P=0.002 P=0.37 P=0.34 P=0.84 P=0.27 P<0.001 P=0.09* P=0.46* P=0.37* P=0.04* Expressed as LS mean change P values for comparison with baseline *P value for comparison with placebo Fibrous Placebo Fibro-fatty Necrotic RVX-208 Calcific

  15. Adverse Clinical and Biochemical Events

  16. Conclusions • Increases in HDL-C and apoA-I and a decrease in LDL-C compared with baseline with RVX-208 did not differ from the placebo group. • For the primary endpoint, a trend to regression with RVX-208 was observed. • For the secondary endpoints, regression of all IVUS measures with RVX-208 did not differ from placebo. • RVX-208 administration was associated with liver enzyme elevations as previously observed.

  17. A Final Thought • Potentially protective properties of HDL has stimulated an immense search for a new therapeutic agent for patients with CAD. • Administration of RVX-208 for 26 weeks did not produce an incremental benefit on atherosclerotic plaque compared with placebo. • The search for benefit of RVX-208 and an effective HDL targeted therapy continues.

More Related